User:Mr. Ibrahem/Ivosidenib

Ivosidenib, sold under the brand name Tibsovo, is a medication used to treat acute myeloid leukemia (AML) and cholangiocarcinoma. Specifically it is used in cases with IDH1 mutations. It is taken by mouth.

Common side effects include diarrhea, tiredness, swelling, nausea, abdominal pain, shortness of breath, QT prolongation, neuropathy, liver problems, low potassium, and kidney problems. Other side effects may include Guillain–Barré syndrome and differentiation syndrome. Use during pregnancy may harm the baby. It is a isocitrate dehydrogenase-1 (IDH1) inhibitor that works by decreasing abnormal production of 2-hydroxyglutarate (2-HG), leading to differentiation of cancer cells.

Ivosidenib was approved for medical use in the United States in 2018. As of 2021 it is not approved in Europe or the United Kingdom. In the United States it costs about 30,000 USD per month as of 2021.